Table 2.
Relation between adverse effects and duration of using topiramate (n=32)
| Duration of the topiramate | |||||
|---|---|---|---|---|---|
| 3 months | 4 months | 5 months | 6 months | Total | |
| Adverse effects | |||||
| No adverse effect | 2 | 1 | 1 | 1 | 5 |
| One adverse effect | 6 | 3 | 3 | 2 | 14 |
| Two adverse effects | 1 | 2 | 1 | 4 | 8 |
| Three adverse effects | 1 | 1 | 1 | 1 | 4 |
| Four adverse effects | 0 | 0 | 0 | 1 | 1 |
| Total | 10 | 7 | 6 | 9 | 32 |
A symptomatic significance (two-sided) P=0.854 (χ2 tests).
P-value is corresponding to χ2 tests – statistical test for the difference between categorical data. P<0.05 is significant.